Ani Pharmaceuticals executive sells $170k in stock By Investing.com

ANI Pharmaceuticals, Inc. (NASDAQ:) has reported a significant transaction involving its shares, according to a recent filing with the Securities and Exchange Commission. Muthusamy Shanmugam, the company’s Head of R&D and COO of Novitium Ops, sold 2,743 shares of common stock on July 18, 2024, for a total of $170,066.

The shares were sold at an average price of $62.00, within a price range of $61.01 to $62.92. The sale was conducted under a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying and selling shares at a time when they are not in possession of material non-public information.

Following the transaction, Shanmugam’s direct holdings in the company decreased, but he still maintains indirect control over additional shares through entities such as Esjay LLC and SS Pharma LLC. Specifically, Esjay LLC holds 63,620 shares, over which Shanmugam has voting and dispositive power. Additionally, SS Pharma LLC holds 5,000 shares with Shanmugam also having voting and dispositive power over these holdings.

The transaction was disclosed in compliance with SEC regulations, which mandate the reporting of insider trading activities. Investors often monitor these filings to gain insights into the actions of company executives and their confidence in the firm’s prospects.

ANI Pharmaceuticals, based in Baudette, Minnesota, specializes in pharmaceutical preparations and has a history dating back to its former names as BioSante Pharmaceuticals Inc. and Ben Abraham Technologies Inc. The company’s commitment to transparency ensures that all transactions are fully disclosed in accordance with regulatory requirements.

In other recent news, ANI Pharmaceuticals has been making significant strides in the healthcare sector. The company has launched a generic version of Endari, L-Glutamine Oral Powder, with the U.S. Food and Drug Administration’s approval. The product’s annual sales in the U.S. are estimated to be around $20.1 million. In addition, ANI Pharmaceuticals has released generic Naproxen Delayed-Release Tablets, a product with a U.S. annual sales estimate of approximately $36.7 million.

The company has also introduced Kionex, a Sodium Polystyrene Sulfonate Suspension USP, which is expected to address a market with limited competition. This product has an estimated annual sales of roughly $30.3 million in the U.S.

ANI Pharmaceuticals has reported a 29% increase in total revenues for the first quarter of 2024, reaching $137.4 million. This includes a significant 126% increase in revenue from Cortrophin Gel, amounting to $36.9 million, and a 10% rise in revenue from the generics business.

Moreover, ANI Pharmaceuticals has acquired Alimera (NASDAQ:) Sciences, a company known for its ophthalmology products, expected to generate $105 million in revenue and over 20% adjusted EBITDA margin for 2024. Following these developments, H.C. Wainwright has raised the stock target for the company. These are part of a series of recent developments at ANI Pharmaceuticals.

InvestingPro Insights

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has shown an interesting financial landscape in the last twelve months as of Q1 2024, which may provide additional context to the recent insider transaction. With a market capitalization of $1.21 billion and a P/E ratio of 37.85, the company seems to be valued at a premium based on its earnings. However, looking ahead, the adjusted P/E ratio for the same period is 59.62, suggesting that investors are expecting higher earnings growth in the future. This aligns with one of the InvestingPro Tips indicating that ANIP’s net income is expected to grow this year.

Revenue growth has been robust, with the company reporting a 44.26% increase in revenue over the last twelve months as of Q1 2024. This is complemented by a strong gross profit margin of 62.71%, which is a positive indicator of the company’s ability to manage its cost of sales and maintain profitability.

From a liquidity standpoint, another InvestingPro Tip for ANIP highlights that the company’s liquid assets exceed its short-term obligations, which suggests financial stability and the ability to cover immediate liabilities.

For investors considering ANIP as a potential addition to their portfolio, it is worth noting that there are 9 additional InvestingPro Tips available at https://www.investing.com/pro/ANIP. These tips can provide deeper insights into ANIP’s financial health and future prospects. Interested individuals can take advantage of the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, offering a comprehensive analysis tool to aid in investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.